IASLC Names Fred R. Hirsch, MD, PhD as New CEO
November 6, 2013 · Comments Off
The International Association for the Study of Lung Cancer (IASLC) Board of Directors has selected Fred R. Hirsch, MD, PhD as the organization’s new Chief Executive Officer (CEO). Hirsch takes over for the current CEO, Paul A. Bunn, Jr., MD.
Study: Redefining the criteria for ALK positive lung cancer
September 10, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.
New marker of drug response may speed pace of lung cancer prevention trials
January 8, 2013 · Comments Off
Testing medicines to prevent lung cancer requires treating many thousands of high-risk individuals and then waiting 5, 10 or 15 years for results. A possible waypoint on the way to benefit may dramatically speed testing.
Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
August 29, 2012 · Comments Off
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark...
Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
August 28, 2012 · Comments Off
Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Prestigious SPECS grant promises targeted treatments for squamous cell lung cancer
March 6, 2012 · Comments Off
THREE KEY POINTS: Fred R. Hirsch will coordinate multimillion dollar, multi site SPECS grant from...
New device uses gold nanoparticles to test for lung cancer
November 16, 2011 · Comments Off
The metabolism of lung cancer patients is different than the metabolism of healthy people. And...
Colorado test helps boost survival rates for lung cancer patients
October 11, 2011 · Comments Off
Researchers at the University of Colorado Cancer Center have developed a test that identifies key...
New combo lung cancer therapy improves survival over single-line treatment
December 14, 2010 · Comments Off
University of Colorado-developed treatment effective in Phase 2 Trials in a biomarker-selected group of patients...
NTRK1: a new oncogene and target in lung cancer
December 14, 2010
A diet of resistant starch helps the body resist colorectal cancer
December 14, 2010
ALK alk drug lung cancer ALL amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno biomarkers bladder cancer breast cancer cancer grants cancer research colorado Cancer Survivorship cell signaling clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma metastasis Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge screening skin cancer tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
Today is the day! Enjoy some blueberry pancakes and dress in all blue for Dress in Blue day to increase... http://t.co/LnYh9iT1lW
One last reminder. Wear blue tomorrow for Dress in Blue Day! http://t.co/dNKEDueKNv
In Health Care, Choice Is Overrated. We're glad our patient got the second opinion needed. Hope others can too. http://t.co/3T9CrAj8E2
President Obama has declared March National Colorectal Cancer Awareness Month! Remember to wear blue this Friday... http://t.co/neqgyKCzAC